Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. Nagasaka M, Zhu VW, Lim SM, Greco M, et al. J Thorac Oncol 2021;16:740-763.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nagasaka M, Zhu VW, Lim SM, Greco M, et al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol 2021;16:740-763.
PMID: 33338652